证券代码：920982 证券简称：锦波生物 公告编号：2026-007 山西锦波生物医药股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 授权委托理财情况 （一）审议情况 山西锦波生物医药股份有限公司（以下简称"公司"）分别于 2025 年 4 月 19 日、2025 年 5 月 21 日召开第四届董事会第八次会议、2024 年年度股东会， 审议通过了《关于使用暂时闲置自有资金购买理财产品的议案》，在不影响公 司主营业务正常发展，并确保经营需求的前提下，公司拟使用不超过人民币 15 亿元的暂时闲置的自有资金购买安全性高、流动性好、风险低的银行理财产品 （包括但不限于银行定期存单、结构性存款或风险低理财产品等），且该等现 金管理产品不得用于质押，不用于以证券投资为目的的投资行为，相关内容详 见公司在北京证券交易所（www.bse.cn）披露的《使用闲置自有资金购买理财 产品的公告》（公告编号：2025-030）。 （二）披露标准 根据《北京证券 ...

从资金流向上来看，当日医疗美容板块主力资金净流出127.97万元，游资资金净流入2832.91万元，散户 资金净流出2704.94万元。医疗美容板块个股资金流向见下表： 证券之星消息，2月4日医疗美容板块较上一交易日上涨0.31%，锦波生物领涨。当日上证指数报收于 4102.2，上涨0.85%。深证成指报收于14156.27，上涨0.21%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 920982 | 锦波生物 | 222.64 | 3.55% | 9236.31 | 2.02 Z | | 000615 | *ST美谷 | 3.13 | 0.97% | 8.45万 | 2651.25万 | | 300896 | 爱美客 | 148.32 | 0.51% | 4.21万 | 6.20 Z | | 688363 | 华熙生物 | 48.80 | -0.02% | 5.81万 | 2.82亿 | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备3101043 ...

证券之星消息，2月3日医疗美容板块较上一交易日上涨3.9%，爱美客领涨。当日上证指数报收于 4067.74，上涨1.29%。深证成指报收于14127.1，上涨2.19%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 147.57 | 4.56% | 6.51万 | | 9.471Z | | 688363 | 华熙生物 | 48.81 | 3.45% | 9.68万 | | 4.68 Z | | 000615 | *ST美谷 | 3.10 | 0.65% | 7.82万 | | 2406.23万 | | 920982 | 锦波生物 | 215.00 | 0.05% | 7358.95 | | 1.57亿 | 从资金流向上来看，当日医疗美容板块主力资金净流入7204.81万元，游资资金净流出3044.38万元，散户 资金净流出4160.43万元。医疗美容板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688363 | 华熙生物 | 47.18 | 5.24% | 11.82万 | | 5.62 亿 | | 300896 | 爱美客 | 141.14 | 1.01% | 4.75万 | | 6.83 亿 | | 000615 | *ST美谷 | 3.08 | 0.33% | 11.51万 | | 3595.71万 | | 920982 | 锦波生物 | 214.89 | -2.94% | 9949.16 | | 2.17亿 | 从资金流向上来看，当日医疗美容板块主力资金净流入1.0亿元，游资资金净流出4045.64万元，散户资金 净流出5989.44万元。医疗美容板块个股资金流向见下表： 证券之星消息，2月2日医疗美容板块较上一交易日上涨2.68%，华熙生物领涨。当日上证指数报收于 4015.75，下跌2.48%。深证成指报收于13824.35，下跌2.69%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 主力净流入 (元 ...

证券之星消息，1月29日医疗美容板块较上一交易日上涨2.96%，爱美客领涨。当日上证指数报收于 4157.98，上涨0.16%。深证成指报收于14300.08，下跌0.3%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 144.38 | 4.53% | 5.67万 | 8.03亿 | | 688363 | 华熙生物 | 46.31 | 1.47% | 4.59万 | 2.11亿 | | 920982 | 锦波生物 | 226.88 | 1.35% | 8287.12 | 1.86 Z | | 000615 | *ST美谷 | 3.13 | -1.26% | 10.31万 | 3232.60万 | 从资金流向上来看，当日医疗美容板块主力资金净流入1.05亿元，游资资金净流出7142.76万元，散户资 金净流出3344.19万元。医疗美容板块个股资金流向见下表： | 代码 | 名称 | 主力净流入 (元) | | | | 主力净占比 游资 ...

从资金流向上来看，当日医疗美容板块主力资金净流出4981.38万元，游资资金净流出538.33万元，散户 资金净流入5519.71万元。医疗美容板块个股资金流向见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.17 | -0.63% | | 6.67万 | | 2120.37万 | | 300896 | 爱美客 | 138.12 | -1.56% | | 2.98万 | | 4.13亿 | | 688363 | 华熙生物 | 45.64 | -1.70% | | 2.88万 | | 1.32亿 | | 920982 | 锦波生物 | 223.85 | -1.97% | | 7323.3 | | 1.65亿 | | 代码 | 名称 | | | 主力净流入（元） 主力净占比 游资净流入（元） 游资净占比 散户净流入 (元) 散户净占比 | | | | | --- | --- | --- | --- | --- | --- ...

证券之星消息，1月27日医疗美容板块较上一交易日下跌1.41%，*ST美谷领跌。当日上证指数报收于 4139.9，上涨0.18%。深证成指报收于14329.91，上涨0.09%。医疗美容板块个股涨跌见下表： 从资金流向上来看，当日医疗美容板块主力资金净流出4131.86万元，游资资金净流出313.41万元，散户 资金净流入4445.27万元。医疗美容板块个股资金流向见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 140.31 | -1.20% | 3.13万 | 4.39 Z | | 920982 | 锦波生物 | 228.34 | -1.31% | 5531.45 | 1.27亿 | | 688363 | 华熙生物 | 46.43 | -1.59% | 4.97万 | 2.29亿 | | 000615 | *ST美谷 | 3.19 | -2.15% | 10.89万 | 3480.46万 | | 代码 | 名称 | | | 主力净流入（元） 主力净占比 ...

| 代码 | 名称 | | | 主力净流入（元） 主力净占比 游资净流入（元） 游资净占比 散户净流入 (元) 散户净占比 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 688363 华盛生物 | | 590.51万 | 2.01% | 1656.31万 | 5.63% | -2246.82万 | -7.64% | | 920982 锦波生物 | | -383.62万 | -1.73% | 491.75万 | 2.21% | -75.65万 | -0.34% | | 000615 *ST美谷 | | -746.45万 | -25.02% | 287.49万 | 9.63% | 458.96万 | 15.38% | | 300896 | 爱美客 | -1314.78万 | -2.68% | -1326.43万 | -2.71% | 2641.21万 | 5.39% | | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- ...

Group 1: Quantum Technology - The report highlights significant advancements in quantum error correction technology, with Zhejiang University and Tsinghua University demonstrating low-overhead quantum error correction codes, effectively reducing logical error rates below physical error rates [4][5] - Horizon Quantum Computing has formed a strategic partnership with Alice&Bob to accelerate the development of fault-tolerant quantum computing, integrating their software and hardware capabilities [5] - GuoDun Quantum plans to sign a technology licensing contract with the University of Science and Technology of China, involving quantum random number generators and superconducting quantum computing control systems [6][7] Group 2: Biomanufacturing - The Chinese Academy of Sciences has achieved a breakthrough in synthesizing L-arginine using methanol as the sole carbon source, marking a shift towards non-grain-based production methods [8][9] - The Shenzhen Advanced Institute has developed the MARS intelligent system, which integrates multiple AI agents and robots to significantly shorten the new material development cycle from four months to four hours [9][10] - Jinbo Biological has registered a 2 billion yuan private placement to enhance its humanized collagen protein FAST database project, aiming to improve research and development efficiency [11] Group 3: Hydrogen Energy and Nuclear Fusion - The Baowu Clean Energy green hydrogen industrial park project, with a total investment of 11.09 billion yuan, has been launched in Guangdong, establishing a new model for offshore wind power direct hydrogen production [12][13] - A Chinese consortium has signed a significant contract for the ITER edge local model power supply system, marking a major step in China's contribution to global fusion energy projects [15] - Zhejiang Fu Nuclear Power will participate in the development of core components for the China Fusion Engineering Demonstration Reactor (CFEDR), focusing on ultra-high heat load components [16][17] Group 4: Brain-Computer Interfaces - Neuralink has successfully implemented OTA wireless upgrades for its invasive brain-computer interface, allowing for performance optimization without the need for additional surgeries [18][19] - This advancement addresses the traditional limitations of invasive devices, reducing clinical maintenance risks and costs while enhancing the adaptability of the technology [20] Group 5: Embodied Intelligence - World Labs, founded by Fei-Fei Li, has partnered with Guanglun Intelligent to create an evaluation system for embodied intelligence, addressing high verification costs and discrepancies between simulation and reality [21][22] - The Marble model developed by World Labs generates high-fidelity 3D environments from various inputs, solving traditional model issues but lacking physical interaction capabilities [22][23] Group 6: Future Industry Catalysts - The report outlines key catalytic events for 2026 across six future industries, including significant conferences and technological milestones that investors should monitor [28][29]

Core Insights - The report highlights a decrease in the market value of public funds heavily invested in the Beijing Stock Exchange (BSE), which reached 9.05 billion yuan as of Q4 2025, a decline of 12.19% quarter-on-quarter [2] - The report indicates that the decline is primarily due to profit-taking by investors in thematic funds, with a total redemption of 1.48 billion units, accounting for 52% of the total units before redemption [2][17] - The average net value growth rate of thematic funds in 2025 was 56.7%, significantly outperforming the BSE 50 index's growth of 38.8% [17] Public Fund Investment Trends - As of Q4 2025, the market value of public funds invested in the BSE accounted for 0.27% of the total A-share market, a decrease of 0.04 percentage points [3][4] - The report notes that passive investment trends are ongoing, with index funds experiencing net subscriptions for three consecutive quarters, totaling 12.838 billion yuan as of Q4 2025, an increase of 7.55 billion yuan [2][13] - The report anticipates continued institutional investment in the BSE, with eight thematic funds pending market entry, including six index funds and two actively managed funds [2] Active Equity Fund Strategies - Active equity public funds are focusing on low-valuation growth stocks, with the valuation center of the top 10 stocks held by these funds dropping to 39 times earnings, below the valuation center of the BSE A-shares [2][20] - Key stocks of interest include Litong Technology (solid-state battery), Tongli Co. (lowest valuation on the BSE), and Lin Tai New Materials (low-valuation high-performance) [2][22] - The report also notes an increased focus on cyclical manufacturing sectors, such as basic chemicals and machinery, while reducing exposure to consumer sectors like beauty care and agriculture [2] Thematic Fund Performance - The report emphasizes that thematic funds have shown significant excess returns, with the average net value growth rate of thematic funds in 2025 being 56.7%, compared to the BSE 50's growth of 38.8% [17] - Specific funds that performed well include the "Hua Xia BSE Innovation Small and Medium Enterprises Selected Two-Year Open Fund," which had the lowest redemption ratio [2][15] - The report identifies a trend of active equity public funds increasing their holdings in stocks like Litong Technology, Tongli Co., and Lin Tai New Materials, indicating a strategic shift towards promising sectors [22]